Articles On Kazia Therapeutics (ASX:KZA)
Title | Source | Codes | Date |
---|---|---|---|
Kazia Therapeutics (ASX:KZA) releases “positive” second-phase study results for brain cancer treatment
Kazia Therapeutics (KZA) opens the trading day green after reporting positive final results from a second-phase clinical study of its paxalisib drug for brain tumours The 30-patient trial confirmed some previously-reported safety and effic... |
themarketherald.com.au | KZA | 2 years ago |
ASX Health Stocks: Alcidion wins Aussie government contract, while Resonance seeks US FDA nod
The ASX 200 Health Index (XHJ) is down by 0.67% at the time of writing, compared to the broader index which is up by 0.47%. Alcidion Group (ASX:ALC) rose nearly 8% this morning, after revealing that it was a member of a consortium awarded a... |
Stockhead | KZA | 2 years ago |
Kazia Therapeutics releases positive final data from Phase 2 trial of glioblastoma treatment paxalisib, shares up
The study tested paxalisib's effectiveness in patients whose genetic profile confers resistance to the only other treatment available for this condition. |
Proactive Investors | KZA | 2 years ago |
GBM AGILE Opens to Paxalisib in Canada
SYDNEY, Nov. 29, 2021 /PRNewswire/ – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to inform stakeholders that the GBM AGILE study in glioblastoma (NCT03970447) has opened a... |
FNArena | KZA | 2 years ago |
Kazia Therapeutics expands further in North America with Toronto glioblastoma study
The Sydney-based company’s flagship drug, paxalisib, is a candidate in a multi-drug platform study designed to identify promising new therapies for glioblastoma. |
Proactive Investors | KZA | 2 years ago |
Dr Boreham’s Crucible: Is Paul Hopper’s star power enough to get Radiopharm Theranostics beaming?
He’s baaack! Fresh from founding and listing immune-oncology play Chimeric, Paul Hopper can add Radiopharm Theranostics (ASX:RAD) to his boardroom rota after the nuclear medicine play listed on the ASX on Thursday – albeit limply. The count... |
Stockhead | KZA | 2 years ago |
Check Up: Sustainable Nutrition riding high and Singular Health branches out from… health
It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining. Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M... |
Stockhead | KZA | 2 years ago |
Top ASX-listed oncology stocks to look at in 2022
Highlights As per experts, the global cancer drug market is likely to accelerate in the upcoming years due to the widespread prevalence of cancer. The increased focus of the healthcare sector on cancer research has been a critical fac... |
Kalkine Media | KZA | 3 years ago |
Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer
SYDNEY, Nov. 16, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the appointment of John Friend, MD, as Chief Medical Officer. In this role,... |
FNArena | KZA | 3 years ago |
Kazia Therapeutics appoints former Cellectar Biosciences chief medical officer John Friend as new CMO
Dr Friend will be responsible for overseeing the development and commercialization of Kazia’s pipeline drug candidates, and collaborate with clinicians and scientists to advance the company’s research programs. |
Proactive Investors | KZA | 3 years ago |
PNOC Study in Childhood Brain Cancer Enrols First Patient
SYDNEY, Nov. 11, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that PNOC022 (NCT05009992), a multi-drug phase II study in DIPG and diffuse mi... |
FNArena | KZA | 3 years ago |
ASX Health Stocks: UBI partners with Mayo Clinic, while Medlab jumps 8pc after divestment
The ASX 200 Health Index (XHJ) is down by 1.0% at the time of writing, compared to the broader index which is down by 0.1%. Medical diagnostics company, Universal Biosensors (ASX:UBI), has entered into a collaboration agreement with Mayo Cl... |
Stockhead | KZA | 3 years ago |
Kazia Therapeutics welcomes start of PNOC study in childhood brain cancer, first patient enrolled
"There remains a desperate need for new treatment options in this disease, and we hope that paxalisib may be able to contribute to better outcomes for patients and their families,” says Kazia CEO. |
Proactive Investors | KZA | 3 years ago |
Market Highlights and 5 ASX Small Caps to watch on Thursday
Wall Street falls as US inflation hits 30-year high US stocks continued their slide overnight, as the latest data showed that consumer prices rose at a pace not seen since the early 1990s. Prices in the US jumped 0.9% in October, and 6.2% f... |
Stockhead | KZA | 3 years ago |
Due Diligence Webinar – Kazia Therapeutics
ShareCafeDue Diligence Webinar – Kazia Therapeutics Presenter – James Garner CEO & Managing Director – Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company based in Sydney, Austral... |
ShareCafe | KZA | 3 years ago |
Kazia Therapeutics marks big step forward as first patient enrols in EVT801 cancer therapy trial
|
Proactive Investors | KZA | 3 years ago |
Kazia Therapeutics (ASX:KZA) enrols first patient in EVT801 trial
Kazia Therapeutics (KZA) enrols its first patient in the upcoming phase one clinical trial of EVT801 EVT801 is a small molecule inhibitor of VEGFR3 and works by hindering lymphangiogenesis, the formation of new lymphatic vessels around the... |
themarketherald.com.au | KZA | 3 years ago |
Kazia Therapeutics enrols first patient to phase I clinical trial of EVT801 cancer therapy
The oncology-focused drug development company licensed the investigational cancer therapy, known as EVT801, from German biotech Evotec AG in April 2021. |
Proactive Investors | KZA | 3 years ago |
ASX Health: Invex gets ready for Phase 3, Medlab gets US patent. Both jump 13pc this morning
The ASX 200 Health Index (XHJ) is up by 0.40% at the time of writing, compared to the broader index which is higher by 0.30%. Neurology specialist, Invex Therapeutics (ASX:IXC), soared 13% after announcing that it’s about to launch a Phase... |
Stockhead | KZA | 3 years ago |
Advanced Human Imaging (ASX:AHI) NASDAQ listing edges closer
ASX-listed mobile health (mHealth) company Advanced Human Imaging (AHI) is moving forward with its planned dual-listing on the NASDAQ exchange Listing on the NASDAQ will place Advanced Human Imaging on one of the highest-quality and highes... |
themarketherald.com.au | KZA | 3 years ago |
Kazia Therapeutics gets boost with ‘buy’ call from Maxim Group and valuation upgrade from Edison
The Maxim Group has also put a 12-month target price of US$18 per ADS, saying the current stock price does not reflect its upside potential. |
Proactive Investors | KZA | 3 years ago |
Kazia Therapeutics’ paxalisib program data garners increased target share price of A$2.83 from Edison
Edison has increased its valuation to A$375 million or A$2.83 per basic share from A$346 million or A$2.68 per basic share mainly due to rolling forward its Net Present Value (NPV). |
Proactive Investors | KZA | 3 years ago |
Kazia Therapeutics to Present at LD Micro Main Event
SYDNEY, Oct. 6, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the LD Micro Main Event, to be he... |
FNArena | KZA | 3 years ago |
Kazia Therapeutics with Proactive at the ASX Small and Mid Cap Conference
|
Proactive Investors | KZA | 3 years ago |
Kazia Therapeutics to Present at HC Wainwright 23rd Annual Global Investment Conference
SYDNEY, Sept. 11, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the HC Wainwright 23rd Annua... |
FNArena | KZA | 3 years ago |
Hidden Gems Webinar Recap – CYP, AT1, NSB & KZA
ShareCafeHidden Gems Webinar Recap – CYP, AT1, NSB & KZA Catch up on the full webinar with presentations from Cynata Therapeutics (ASX: CYP), Atomo Diagnostics (ASX: AT1), NeuroScientific (ASX: NSB) & Kazia Therapeutics (ASX: KZA)... |
ShareCafe | KZA | 3 years ago |
A high quality pipeline of cancer drugs
ShareCafeA high quality pipeline of cancer drugs James Garner – Managing Director & CEO – Kazia Therapeutics Limited is an innovative oncology-focused biotechnology company. Kazia is working to develop therapies across a range of on... |
ShareCafe | KZA | 3 years ago |
Check Up: Dimerix and ImpediMed announced breakthroughs, while earnings dominate news flow in August
Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat... |
Stockhead | KZA | 3 years ago |
Kazia Therapeutics directors support oncology-focused drug strategy with on-market purchases
“The second calendar quarter has been a busy and productive period for Kazia, as we bed down three substantial cross-border licensing deals,” says CEO. |
Proactive Investors | KZA | 3 years ago |
Kazia Therapeutics eyeing commercialisation revenue after “game-changing” FY21
Kazia says its future success will be measured by commercialisation milestones after the company recorded its maiden revenue in the 2021 financial year. |
Proactive Investors | KZA | 3 years ago |
Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress
It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N... |
Stockhead | KZA | 3 years ago |
Check Up: Hexima roars 70pc on clinical trials, while Bionomics heads for a US dual listing
The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du... |
Stockhead | KZA | 3 years ago |
Kazia Therapeutics has 'busy and productive' June quarter with important readouts slated for second half
All upfront payments from outbound partnering transactions in the first quarter have been received by Kazia. |
Proactive Investors | KZA | 3 years ago |
Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day
SYDNEY, July 21, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a leading drug development company in the field of brain cancer, today recognizes Glioblastoma (GBM) Awareness Day and calls for a greater focus on re... |
FNArena | KZA | 3 years ago |
Check Up: Rhythm (ASX:RHY) plans US expansion, the US$1.5b dog dermatitis market and data dumps drive stocks down
It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by Rhinomed (ASX:RNO)... |
Stockhead | KZA | 3 years ago |
Check up: A mixed bag for ASX health stocks as FDA decides fates at the flip of a coin
It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals... |
Stockhead | KZA | 3 years ago |
3 ASX healthcare shares with big news coming
The fortunes of ASX healthcare shares can often swing on one momentous milestone. Examples of such a make-or-break event could be a breakthrough invention, successful product trial, or regulatory approval (or rejection). Such incidents can... |
Motley Fool | KZA | 3 years ago |
Kazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs
SYDNEY, June 30, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update on recent progress with its two pipeline assets, paxalisib and EVT801... |
FNArena | KZA | 3 years ago |
Kazia Therapeutics makes strong progress with clinical programs for paxalisib and EVT801
The GBM AGILE pivotal study of paxalisib is recruiting ahead of expectations, with almost 25 sites now open to the paxalisib arm in the US across several prestigious centres. |
Proactive Investors | KZA | 3 years ago |
The Information Technology stocks that created buzz today!
Summary Afterpay jumps on plans to expand reach with U.S. merchants Althea enters South African cannabis market worth US$667 million Bluechiip shares close strong on a settlement agreement with Labcon North America The S&P/ASX... |
Kalkine Media | KZA | 3 years ago |
ASX ends lower for 2nd day in a row; tech, iron ore stocks fail to lift market sentiment
Summary The ASX 200 closed lower for the second day in a row, falling 0.32% to 7,275.30. The ASX health care and energy stocks were among top losers, while tech and consumer staples emerged as top gainers. Australian retailer Woolwort... |
Kalkine Media | KZA | 3 years ago |
Kazia Therapeutics lands key manufacturing patents for paxalisib in US and India
A Kazia-licensed oncology drug has secured manufacturing patents in two key countries, providing an additional layer of protection for the treatment candidate over the next 15 years. |
Proactive Investors | KZA | 3 years ago |
Kazia Therapeutics secures new patents for manufacturing process
Oncology-focused drug development company Kazia Therapeutics (ASX:KZA) has announced the grant of patents by the respective agencies of the US and India for the manufacturing process for paxalisib. |
BiotechDispatch | KZA | 3 years ago |
As neuroscience blurs the line between tech and biology, these ASX brain health stocks are on the frontline
Recent advances in our still-shallow understanding of the human brain have led to a renewed interest in companies that focus on neuroscience. The most famous neuroscience startup, Elon Musk’s Neuralink, is probably the first company that co... |
Stockhead | KZA | 3 years ago |
Kazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma
SYDNEY, June 15, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it has entered a collaboration with the Joan & Sanford I Weill Medica... |
FNArena | KZA | 3 years ago |
Here’s why the Kazia Therapeutics (ASX:KZA) share price got a 6% boost today
Shares in Kazia Therapeutics Ltd (ASX: KZA) lifted today after news its investigational drug Paxalisib will be part of another study for the treatment of brain cancer. At market close, the Kazia share price is $1.40 – 6.87% higher than its... |
Motley Fool | KZA | 3 years ago |
Kazia Therapeutics to collaborate with Cornell University for new paxalisib phase II clinical trial
A new study will evaluate the efficacy of Kazia’s paxalisib candidate in patients with newly diagnosed or recurrent glioblastoma when combined with a ketogenic diet and metformin. |
Proactive Investors | KZA | 3 years ago |
Alzheimer’s Decision Sends Positive Message to Aussie Biotechs
ShareCafeAlzheimer’s Decision Sends Positive Message to Aussie Biotechs The US Food and Drug Administration’s landmark but controversial approval of a new treatment for Alzheimer’s disease suggests a sea change in the regulator’s attitude t... |
ShareCafe | KZA | 3 years ago |
Check Up: As Alzheimer’s grabs the spotlight, these ASX biotech stocks also impressed
Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U... |
Stockhead | KZA | 3 years ago |
Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient
SYDNEY, June 7, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia’s investigational new drug, paxalisib, in primar... |
FNArena | KZA | 3 years ago |